What is Invasive Aspergillosis?

Invasive aspergillosis, a leading infection-caused death in immunocompromised patients, is a serious fungal infection caused by Aspergillus species. Current treatment guidelines recommend the use of azoles as the initial first-line therapy. However, patients face unsatisfactory clinical outcomes, with mortality rates up to 50% and long treatment durations. Current therapies also often exhibit drug-drug interactions, and the recent emergence of A. fumigatus azole resistance is increasingly becoming a clinical concern worldwide.

Due to the significant rate of resistance in some countries, combination antifungal therapy is recommended as first-line treatment for patients suspected of invasive aspergillosis. We believe that ibrexafungerp's broad activity against Aspergillus spp., including azole-resistant strains, along with its minimal drug-drug interactions, high tissue penetration into the lungs and oral formulation allowing for long-term administration, may make it an ideal candidate for use as combination therapy.